There is limited information on gender- and age-specific effects on plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone. The present study investigated dose- and weight-adjusted plasma concentrations of risperidone and its metabolite in three age groups (45 years, 45-60 years, over 60 years). Gender-specific differences were examined in the whole sample and for the premenopausal subgroup. One hundred and twenty-nine patients (18-93 years) were included in the study, 52 (40%) male and 77 (60%) female. Concentrations of risperidone and 9-hydroxyrisperidone were measured at steady-state by high-performance liquid chromatography with electrochemical detection (HPLC-ED). When total plasma concentrations (risperidone plus 9-hydroxyrisperidone) were adjusted for daily maintenance dose (ng/mL/mg C/D ratio), significant differences between all age groups were found. We found a mean increase of the C/D ratio by 34.8% per decade in patients older than 42 years. No significant sex-related differences in the average plasma concentrations were observed for the whole sample and for the premenopausal subgroup. This study shows clear evidence of higher risperidone total plasma concentrations for patients over 40 years of age. This linear increase (over 30% per decade) may then lead to an increased incidence of adverse effects in elderly patients.
Balant-Gorgia A E , Gex-Fabry M , Genet C , Balant L P (1999) Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reap praisal of interindividual variability factors . Ther Drug Monit21: 105-115
2.
Brodaty H , Ames D , Snowdon J , Woodward M , Kirwan J , Clarnette R , Lee E , Lyons B , Grossman F (2003) A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psy chosis of dementia . J Clin Psychiatry64: 134-143
3.
Carrillo J A , Herraiz A G , Ramos S I , Gervasini G , Vizcaino S , Benitez J (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine . J Clin Psychopharmacol23: 119-127
4.
Catlow J T , Barton R D , Clemens M , Gillespie T A , Goodwin M , Swanson S P (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection . J Chromatogr B Biomed Appl668: 85-90
5.
Catterson M L , Preskorn S H , Martin R L (1997) Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology . Psychiatr Clin North Am20: 205-218
6.
Chandler M H , Scott S R , Blouin R A (1988) Age-associated stereoselective alterations in hexobarbital metabolism . Clin Pharmacol Ther43: 436-441
7.
Chouinard G , Arnott W (1993) Clinical review of risperidone . Can J Psychiatry38 (Suppl. 3): S89-S95
8.
Dawling S , Crome P (1989) Clinical pharmacokinetic considerations in the elderly: an update . Clin Pharmacokinet17: 236-263
9.
Fang J , Bourin M , Baker G B (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 . Naunyn Schmiedebergs Arch Pharmacol359: 147-151
10.
Fletcher C V , Acosta E P , Strykowski J M (1994) Gender differences in human pharmacokinetics and pharmacodynamics . J Adolesc Health15: 619-629
11.
Hagg S , Spigset O , Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers . Br J Clin Pharmacol51: 169-173
12.
Haring C , Humpel C , Auer B , Saria A , Barnas C , Fleischhacker W , Hinter-huber H (1988) Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection . J Chromatogr428: 160-166
13.
Harris R Z , Benet L Z , Schwartz J B (1995) Gender effects in pharmacokinetics and pharmacodynamics . Drugs50: 222-239
14.
Heykants J , Huang M L , Mannens G , Meuldermans W , Snoeck E , Van Beijsterveldt L , Van Peer A , Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary . J Clin Psychiatry55(Suppl.): 13-17
15.
Hulst L K , Fleishaker J C , Peters G R , Harry J D , Wright D M , Ward P (1994) Effect of age and gender on tirilazad pharmacokinetics in humans . Clin Pharmacol Ther55: 378-384
16.
Hunt C M , Westerkam W R , Stave G M (1992) Effect of age and gender on the activity of human hepatic CYP3A . Biochem Pharmacol44: 275-283
17.
Janssen P A , Niemegeers C J , Awouters F , Schellekens K H , Megens A A , Meert T F (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties . J Pharmacol Exp Ther244: 685-693
18.
Kelly D L , Conley R R , Tamminga C A (1999) Differential olanzapine plasma concentrations by sex in a fixed-dose study . Schizophr Res40: 101-104
19.
Le Couteur D G , McLean A J (1998) The aging liver . Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet34: 359-373
20.
Le Moing J P , Edouard S , Levron J C (1993) Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with electrochemical detection . J Chromatogr614: 333-339
21.
Ludden T M , Beal S L , Sheiner L B (1994) Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection . J Pharmacokinet Biopharm22: 431-445
22.
McCune J S , Lindley C , Decker J L , Williamson K M , Meadowcroft A M , Graff D , Sawyer W T , Blough D K , Pieper J A (2001) Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan . J Clin Pharmacol41: 723-731
23.
Mannens G , Huang M L , Meuldermans W , Hendrickx J , Woestenborghs R , Heykants J (1993) Absorption, metabolism, and excretion of risperi-done in humans . Drug Metab Dispos21: 1134-1141
24.
Miglioli P A , Pivetta P , Strazzabosco M , Orlando R , Okolicsanyi L , Palatini P (1990) Effect of age on single- and multiple-dose pharmacokinetics of erythromycin . Eur J Clin Pharmacol39: 161-164
25.
Motulsky, H , Christopoulos, A (2003) Fitting Models to Biological Data Using Linear and Nonlinear Regression. GraphPad Software Inc.
26.
Robertson D R , Waller D G , Renwick A G , George C F (1988) Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine . Br J Clin Pharmacol25: 297-305
27.
Snoeck E , Van Peer A , Sack M , Horton M , Mannens G , Woestenborghs R , Meibach R , Heykants J (1995) Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man . Psychopharmacology (Berl)122: 223-229
28.
Sotaniemi E A , Arranto A J , Pelkonen O , Pasanen M (1997) Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions . Clin Pharmacol Ther61: 331-339
29.
Spina E , Avenoso A , Facciola G , Salemi M , Scordo M G , Ancione M , Madia A G , Perucca E (2001a) Relationship between plasma risperi-done and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia . Psychopharmacology (Berl)153: 238-243
30.
Spina E , Avenoso A , Facciola G , Scordo M G , Ancione M , Madia A (2001b) Plasma concentrations of risperidone and 9-hydroxyrisperi-done during combined treatment with paroxetine . Ther Drug Monit23: 223-227
31.
Tamminga W J , Wemer J , Oosterhuis B , Weiling J , Wilffert B , de Leij L F , de Zeeuw R A , Jonkman J H (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences . Eur J Clin Pharmacol55: 177-184
32.
Van Beijsterveldt L E , Geerts R J , Leysen J E , Megens A A , Van den Eynde H M , Meuldermans W E , Heykants J J (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperi-done in the rat . Psychopharmacology (Berl)114: 53-62
33.
Wadelius M , Darj E , Frenne G , Rane A (1997) Induction of CYP2D6 in pregnancy . Clin Pharmacol Ther62: 400-407
34.
Wirshing D A , Marshall B D, Jr , Green M F , Mintz J , Marder S R , Wirshing W C (1999) Risperidone in treatment-refractory schizophrenia . Am J Psychiatry156: 1374-1379
35.
World Health Organization . Manual of the International Classification of Diseases (ICD-10). WHO, Geneva
36.
Yoshimura R , Ueda N , Nakamura J (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperi-done and extrapyramidal symptoms . Preliminary study. Neuropsychobiology44: 129-133
37.
Zhang X Y , Zhou D F , Cao L Y , Zhang P Y , Wu G Y , Shen Y C (2001) Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study . Int Clin Psychopharmacol16: 325-330
38.
Zourkova A , Hadasova E (2003) Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects . Gen Physiol Biophys22: 103-113
